Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study혈액종양 환자 및 의료 종사자에 대한 SARS-CoV-2 백신 3차 접종: 면역 반응 및 부작용 - 후향적 코호트 연구Article Published on 2022-04-012022-09-11 Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), SARS, 변종, [키워드] Adverse adverse event adverse events Analysis anti-S anti-SARS-CoV-2 antibody antibody levels B cell Cancer Care CD19 CD19+ CD56 CD56+ Cell chills Community community hospital Control correlated COVID-19 decrease dose event fatigue follow-up study haematological malignancies haematological malignancy HCW Health Health care Health care worker hospital immune response increasingly Italy local pain longitudinal longitudinal analysis Lower malignancy NK cell oncology other treatment other treatments Patient Patients with cancer patients with haematological Peripheral blood Questionnaires receiving retrieved retrospective cohort study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination second vaccination Side-effect solid tumour Spike protein therapy trials Tumours vaccination virus variant waning immunity [DOI] 10.1016/j.ejca.2022.01.019 PMC 바로가기 [Article Type] Article
Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19COVID-19 환자의 림프구 하위 집합 및 사이토카인 프로필의 특성Article Published on 2022-03-282022-09-11 Journal: Virology Journal [Category] 변종, 치료기술, [키워드] Abnormalities age Analysis analyzed AUC B cells Care CD19 CD3 CD4 CD8 Cell Chongqing clinical Clinical and laboratory data coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Critical cutoff value cytokine cytokine profile Cytokines diabetes Diabetes Mellitus enrolled evaluate Factor Hospital admission ICU ICU admission ICU patient ICU Patients IL-6 independent predictor independent predictors Infection interleukin laboratory data Logistic regression Logistic regression analysis lymphocyte Lymphocyte subset Lymphocyte subsets Lymphocytes lymphopenia Most patients multivariate multivariate logistic regression analysis mutant natural killer no statistical difference No statistical differences non-ICU non-ICU patient non-ICU patients Odds ratio Patient patients patients with COVID-19 peripheral lymphocyte Predictive Predictive value receiver operating characteristic ROC ROC Curve selected sensitivity severe disease severe group severity severity of COVID-19 significantly significantly higher specificity statistical differences subset T cell T cells tested the disease Three Gorge Three Gorges treated university virus infection was used wild-type virus [DOI] 10.1186/s12985-022-01786-2 PMC 바로가기 [Article Type] Article
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment항-CD20 단일클론항체는 치료 후 6개월 이내에 비호지킨 림프종 환자에서 Covid-19 예방접종에 대한 혈청양성 반응을 억제합니다Article Published on 2022-03-012022-09-12 Journal: Experimental hematology [Category] MERS, SARS, 진단, 치료법, [키워드] anti-CD20 anti-CD20 treatment B cell caused CD19 death Efficacy immunosuppressive indicated inhibit less lymphocyte lymphoma monoclonal antibodies monoclonal antibody Non-Hodgkin Lymphoma pandemic Patient Pfizer-BioNTech Prevent respond seropositive the healthy the vaccine therapy treated Treatment vaccination Vaccine volunteers [DOI] 10.1016/j.exphem.2021.12.396 PMC 바로가기 [Article Type] Article
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and functionClinical Medicine Published on 2022-02-222022-10-30 Journal: JCI Insight [Category] COVID-19, COVID19(2023년), SARS, [키워드] Acetate adaptive Adaptive immunity Affect anti-CD20 antibody Autoimmunity B cell CD19 CD4 CD8 cellular immunity characterized Clinical guidelines Cohort correlated COVID-19 cumulative cytokine expression Effect epitope foundation fumarate functional groups healthy control humoral IgG level Immunity Immunotherapy implication large cohort Luminex assay mAbs marker Multiple multiple sclerosis neutralization NIH participant Patient patients pseudovirus Quantitative reactivity receiving receptor reduced remained response robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination spike Study participants T cell T cell response T cell responses therapy treated Treatment were assessed were measured [DOI] 10.1172/jci.insight.156978 PMC 바로가기 [Article Type] Clinical Medicine
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapyCD19 CAR T 세포 치료 후 B 세포 악성 종양 환자에서 COVID-19 예방 접종에 대한 면역 반응 손상Article Published on 2022-01-252022-09-11 Journal: Blood advances [Category] SARS, 바이오마커, [키워드] B-cell malignancy CAR CD19 COVID-19 vaccination immune response Impaired Patient T-cell therapy [DOI] 10.1182/bloodadvances.2021006112 PMC 바로가기 [Article Type] Article
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab오파투무맙으로 치료받은 다발성 경화증 환자의 회복기 COVID-19 환자의 체액 및 세포 면역Article Published on 2022-01-152022-09-11 Journal: Journal of neuroimmunology [Category] 임상, 진단, [키워드] Administered all subject all subjects antibodies Antibody Response Antibody testing CD19 CD19+ Cell cellular immunity Clinical outcome convalescent COVID-19 COVID-19 infection COVID-19 symptoms COVID-19 vaccination COVID-19 vaccinations dose ELISPOT four subject humoral IgG antibodies IgG antibody IgM IgM and IgG Immunity interferon interferon-γ lymphocyte mediated immunity Mild Multiple multiple sclerosis not performed Ofatumumab PCR performed Quotient reactive SARS-CoV-2 secreting single center subject T cell T-cell T-cell immunity Testing treated U/mL was performed was used while [DOI] 10.1016/j.jneuroim.2021.577788 PMC 바로가기 [Article Type] Article
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia이전에 항-CD20 단일클론 항체 매개 B 세포 고갈 및 만성 림프구성 백혈병이 있는 환자에서 장기간 바이러스 SARS-CoV-2 복제에 대한 성공적인 구조 치료제로서의 플리티뎁신Case Reports Published on 2022-01-102022-09-10 Journal: Journal of Hematology & Oncology [Category] SARS, 바이오마커, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected anti-CD20 Anti-CD20 monoclonal antibody Antiviral antiviral drug antiviral therapies antiviral therapy B cell CD19 CD20 chronic lymphocytic leukemia compassionate use coronavirus coronavirus disease Course COVID-19 COVID-19 pneumonia deficiency develop hematological Hematological malignancies Host immune Immune deficiencies Immunosuppressed Infection leukemia Lymphocytic leukemia male monoclonal monoclonal antibodies Patient Plitidepsin Pneumonia Population Prolonged viral replication resolved respiratory SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients SARS-CoV-2 replication Severe COVID-19 pneumonia supplementary material Support toxicities treated Treatment treatment with anti-CD20 undetectable Viral Viral load [DOI] 10.1186/s13045-021-01220-0 PMC 바로가기 [Article Type] Case Reports
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab오크렐리주맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 체액 및 T 세포 반응Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] Absolute lymphocyte count adaptive Adaptive Biotechnology age analyzed anti-CD20 therapy Anti-SARS-CoV-2 S antibodies antibody Antibody Response B and T-cell BMI CD19 characterized chemotherapeutic agents cohort study comparator conducted coronavirus coronavirus vaccine COVID COVID-19 COVID-19 epidemic Descriptive statistics detectable determine did not produce Efficacy Elecsy Eligible patients enrolled Enrollment evaluate Fisher Fisher's exact test had no humoral Humoral response IgG immune response immunoassay immunogenicity Immunoglobulin Immunoglobulin G immunosuppressive impair Infection likelihood lymphocyte Multiple multiple sclerosis Natalizumab negative antibody response no correlation Ocrelizumab Patient patients patients treated positive positive antibody response post vaccination Prevent producing question raise reduce Research response Roche SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination severity Sex shown single center T-cell T-cell Response T-cell responses Test the antibody response treated Treatment vaccination Vaccine vaccine immunogenicity variable was performed were excluded Wilcoxon rank sum [DOI] 10.1016/j.msard.2021.103382 PMC 바로가기 [Article Type] Article
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosisocrelizumab, alemtuzumab 및 cladribine 후 CD19 B 세포 재증식: 다발성 경화증에서 SARS-CoV-2 예방 접종에 대한 의미Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] SARS, 진단, [키워드] Alemtuzumab B cell B-cell CD19 CD20 Cladribine clinical trial Control Controlled determine dosing interval exhibited extension facilitate Frequency inhibit lymphocyte maintain MOST Multiple multiple sclerosis occurred Ocrelizumab Relapse relapsing rituximab SARS-CoV-2 vaccination Seroconversion seroconvert Standard therapy Tablet Treatment Trial vaccination [DOI] 10.1016/j.msard.2021.103448 PMC 바로가기 [Article Type] Article
CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients면역 저하 환자에서 COVID 19 mRNA 백신 접종에 대한 체액 반응의 예측 인자로서의 CD19+IgD+CD27- 나이브 B 세포Clinical Trial Published on 2021-12-072022-09-12 Journal: Frontiers in Immunology [Category] SARS, 임상, 진단, [키워드] 95%CI Analysis analyzed anti-SARS-CoV-2 antibody Antibody Response B cells B-cell Cancer cause CD19 CD27 circulating comparable COVID 19 COVID-19 cut-off healthy control healthy controls hematologic Hematologic malignancy humoral identify IGD immunoassay Immunocompromised Immunocompromised patients immunodeficiencies immunodeficiency independent mRNA mRNA vaccine naïve B cell occurred Patient performed predictor RBD receiver operating characteristic response second vaccination subset the receptor-binding domain trimeric S protein vaccination vaccination against COVID-19 [DOI] 10.3389/fimmu.2021.803742 PMC 바로가기 [Article Type] Clinical Trial